Literature DB >> 12006342

Leflunomide and hypertension.

B Rozman, S Praprotnik, D Logar, M Tomsic, M Hojnik, M Kos-Golja, R Accetto, P Dolenc.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12006342      PMCID： PMC1754107          DOI： 10.1136/ard.61.6.567

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  27 in total

1.  Inflammation and hypertension in rheumatoid arthritis.

Authors:  Siriporn Manavathongchai; Aihua Bian; Young Hee Rho; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  J Rheumatol       Date:  2013-09-01       Impact factor: 4.666

Review 2.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

3.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 4.  Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.

Authors:  Debbie T Lim; Amy C Cannella; Kaleb D Michaud; Ted R Mikuls
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

Review 5.  Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins.

Authors:  Radjesh J Bisoendial; Erik S G Stroes; John J P Kastelein; Paul Peter Tak
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

6.  Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients.

Authors:  S Yoshida; T Takeuchi; T Kotani; N Yamamoto; K Hata; K Nagai; T Shoda; S Takai; S Makino; T Hanafusa
Journal:  J Hum Hypertens       Date:  2013-09-05       Impact factor: 3.012

7.  Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.

Authors:  Rishi J Desai; Daniel H Solomon; Sebastian Schneeweiss; Goodarz Danaei; Katherine P Liao; Seoyoung C Kim
Journal:  Epidemiology       Date:  2016-05       Impact factor: 4.822

8.  Review of teriflunomide and its potential in the treatment of multiple sclerosis.

Authors:  Clemens Warnke; Gerd Meyer zu Hörste; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

9.  Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Karen M J Douglas; Helen R Griffiths; George D Kitas
Journal:  Arthritis Res Ther       Date:  2008-12-17       Impact factor: 5.156

10.  Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors.

Authors:  Young Hee Rho; Annette Oeser; Cecilia P Chung; Ginger L Milne; C Michael Stein
Journal:  Arch Drug Inf       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.